Loading...
Loading...
Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) today announced that its subsidiary, Cardiome Development AG,
has entered into an agreement with LifePharma (Z.A.M) Ltd., to sell and
distribute BRINAVESS™ (vernakalant intravenous) exclusively in Cyprus.
Under the terms of the agreement, LifePharma has agreed to specific
annual commercial goals for BRINAVESS. Financial details of the
agreement were not disclosed.
"We are pleased to enter into this agreement with LifePharma and
continue to have BRINAVESS available to our customers in Cyprus," said
Karim Lalji, Cardiome's Chief Commercial Officer. "LifePharma is a
pharmaceutical industry leader in Cyprus and we are excited to leverage
their deep expertise in this market."
"We are pleased to have partnered with Cardiome to commercialize
BRINAVESS in Cyprus," said Savvas Jacovides, President of the Board of
Directors of LifePharma (Z.A.M) Ltd. "Our customers will be delighted
to know that access to BRINAVESS will continue through LifePharma and
that we are committed to meeting their needs to have the product
available."
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in